Welcome to our dedicated page for Inozyme Pharma SEC filings (Ticker: INZY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing loaded with pharmacokinetic charts, trial protocols, and revenue-less cash-flow tables can feel overwhelming. Inozyme Pharma鈥檚 SEC disclosures are especially dense because every 10-Q must outline patient-enrollment updates, orphan-drug milestones, and runway projections. Investors who just want to know whether INZ-701 hit a safety endpoint鈥攐r if directors are accumulating stock鈥攕houldn鈥檛 wade through 200 pages.
Stock Titan turns those complexities into clarity. Our AI-powered summaries flag exactly where 鈥渦nderstanding Inozyme Pharma SEC documents with AI鈥� matters: the section explaining ENPP1 and ABCC6 data in the Inozyme Pharma quarterly earnings report 10-Q filing, risk-factor shifts in the Inozyme Pharma annual report 10-K simplified, and any surprise Inozyme Pharma 8-K material events explained. AG真人官方-time alerts on Inozyme Pharma insider trading Form 4 transactions and Inozyme Pharma executive stock transactions Form 4 arrive seconds after EDGAR posts, letting you gauge leadership sentiment before the market reacts.
Every filing type is covered鈥攆rom the Inozyme Pharma proxy statement executive compensation that details option grants to the S-3 shelf registration outlining future capital needs. Use our platform to:
- Compare R&D spend across periods with the Inozyme Pharma earnings report filing analysis.
- Track each Inozyme Pharma Form 4 insider transactions real-time notice for buying or selling patterns.
- Download study-level data tables straight from exhibits without searching.
Whether you ask, 鈥淲hat does Inozyme Pharma report in their SEC filings?鈥� or 鈥淲here can I find an Inozyme Pharma quarterly earnings report 10-Q filing?鈥�, you鈥檒l land here. Explore 鈥淚nozyme Pharma SEC filings explained simply鈥� and move from raw data to actionable insight in minutes鈥擜I explained, investor approved.
Inozyme Pharma COO Matthew Winton acquired 14,355 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP). The shares were purchased at $0.74 per share, representing 85% of the closing price on April 1, 2025, the first day of the purchase period.
Following this transaction, Winton's direct beneficial ownership increased to 21,743 shares. The purchase was made during the ESPP period running from April 1, 2025, through June 25, 2025.
- Transaction Type: Stock Purchase through ESPP
- Purchase Price: $0.74 per share (15% discount)
- Ownership Form: Direct
- Filing Status: Individual filing
This insider purchase through the ESPP demonstrates continued participation in company equity programs by key executive leadership.
Insider Trading Alert: Douglas A. Treco, CEO & Chairman of Inozyme Pharma (NASDAQ: INZY), acquired 2,815 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP).
Key Transaction Details:
- Purchase price: $0.74 per share (85% of closing price on April 1, 2025)
- Total shares owned after transaction: 43,861 shares
- Ownership type: Direct
- ESPP purchase period: April 1, 2025 - June 25, 2025
The transaction was executed under the company's 2020 ESPP, which allows employees to purchase company stock at a discount. This insider purchase by the CEO demonstrates continued alignment with shareholder interests and potential confidence in the company's prospects.
Inozyme Pharma (INZY) SVP, CFO & Head of BD Sanjay Subramanian reported the acquisition of 6,813 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP).
Key transaction details:
- Purchase price: $0.74 per share (85% of closing price on April 1, 2025)
- ESPP purchase period: April 1, 2025 - June 25, 2025
- Total shares owned after transaction: 39,701 shares
- Ownership form: Direct
This insider purchase through the ESPP demonstrates continued participation in company equity programs by a key executive officer. The transaction was executed under the company's 2020 Employee Stock Purchase Plan, which allows employees to purchase shares at a discount to market price.
Inozyme Pharma has announced the postponement of its 2025 Annual Meeting of Stockholders, originally scheduled for June 25, 2025, due to a pending acquisition by BioMarin Pharmaceutical. If the acquisition completes, no public stockholder annual meeting will be held. If it doesn't proceed, the Board will reschedule the meeting with a new record date.
Key Company Profile:
- Clinical-stage biopharmaceutical company with ~50 Boston-based employees
- Focuses on PPi-Adenosine Pathway therapeutics for bone health and blood vessel function
- Lead therapy INZ-701, an ENPP1 Fc fusion protein, is in late-stage clinical trials
- Target conditions include ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis
The filing includes detailed information about the tender offer process and directs stockholders to review important acquisition-related documents filed with the SEC by both companies. Materials are available on the SEC website and both companies' respective websites.
Inozyme Pharma, Inc. (Nasdaq: INZY) filed a Form 8-K on June 20, 2025 to disclose that it has postponed its 2025 Annual Meeting of Stockholders in light of the previously announced acquisition by BioMarin Pharmaceutical Inc. The decision is detailed in a press release attached as Exhibit 99.1; an Inline XBRL cover-page file is included as Exhibit 104.
The report stresses that the tender-offer process is governed by documents already on file with the SEC: BioMarin and Incline Merger Sub鈥檚 Schedule TO (Offer to Purchase, Letter of Transmittal and related materials) and Inozyme鈥檚 Schedule 14D-9 Solicitation/Recommendation Statement. Investors are urged to review these materials, which are available without charge on www.sec.gov and the companies鈥� investor-relations websites.
No financial statements, operating metrics or earnings information accompany this current report. The filing is limited to the postponement notice and related procedural information regarding the pending transaction.
FAQ
What is the current stock price of Inozyme Pharma (INZY)?
What is the market cap of Inozyme Pharma (INZY)?
